NICE Proves Cost Is Not Everything, Clears Two High-Priced Skin Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s Zelboraf and Bristol-Myers Squibb’s Yervoy exceed NICE’s cost-effectiveness limit, but are still waved through as targeting unmet medical need.